South Korea’s antitrust agency on July 20 imposed fines of ₩40.9 billion (US$31.9 million) to crack down on 32 pharmaceutical firms charged with colluding on production, distribution and wholesale of vaccines in the country’s immunization program.
South Korea’s antitrust agency on July 20 imposed fines of ₩40.9 billion (US$31.9 million) to crack down on 32 pharmaceutical firms charged with colluding on production, distribution and wholesale of vaccines in the country’s immunization program.
South Korean pharmaceutical giant Yuhan Corp. gained Korea’s MFDS approval to expand indications for its potent oral third-generation tyrosine kinase inhibitor Leclaza (lazertinib) as a first-line treatment for EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC).
South Korean pharmaceutical giant Yuhan Corp. gained Korea’s MFDS approval to expand indications for its potent oral third-generation tyrosine kinase inhibitor Leclaza (lazertinib) as a first-line treatment for EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC).
Lysyl oxidase homologue 2 (LOXL2) inhibitors have been reported in a Yuhan Corp. patent as potentially useful for the treatment of idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis (NASH), chronic kidney disease and cirrhosis.
Janssen Biotech Inc. and Yuhan Corp. have synthesized substituted aminopyridine compounds acting as EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Trophoblast glycoprotein, also known as 5T4, is widely expressed in several solid tumors; cluster of differentiation 47 (CD47) is an ubiquitous immune checkpoint receptor that is also overexpressed in many solid tumors as well as in hematological cancers. A Yuhan Corp. research team has presented preclinical results on YH-38560, a bispecific fusion protein that targets both 5T4 and CD4 for the potential treatment of solid tumors.
HONG KONG – South Korean pharmaceutical giant Yuhan Corp. has invested ₩3 billion (US$2.6 million) in SL Bigen Co. Ltd., a Korean biotech based in Seongnam, Gyeonggi-do, that is focused on chimeric antigen receptor-directed natural killer (CAR-NK) therapy.
HONG KONG – South Korean pharmaceutical giant Yuhan Corp. has invested ₩3 billion (US$2.6 million) in SL Bigen Co. Ltd., a Korean biotech based in Seongnam, Gyeonggi-do, that is focused on chimeric antigen receptor-directed natural killer (CAR-NK) therapy.
